IAP12 Rec'd PCT/PTO 1 0 MAY 2006

MODIFIED PTO/SB/08 A & B (08-03)

bstitute for Form.1449 A & B/PTO			Comp	Complete if kn 4578836		
Distitute for Pormit	4) Y @ D/ 10		Application Number	Unknown		
INFO	RMATION	DISCLOSURE	Confirmation Number	Unknown		
STATEMENT BY APPLICANT			Filing Date	May 9, 2006		
SIAI	ENERT D	AFFLICANT	First Named Inventor	Junho CHUNG		
(use as many sheets as necessary)			Art Unit	Unknown		
			Examiner Name	Unknown		
Sheet	1	of 1	Attorney Docket Number	Q94845		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Dublication Date		
		Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		US				
		US				
		US				
		US				
		US				
į		US				
		US				

FOREIGN PATENT DOCUMENTS							
	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		-					
		L,					

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		B. Cao et al., "Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models", PNAS, June 2001, Vol. 98(13): pp. 7443-7448.			
		M. Tokunou et al., ""c-Met expression in myofibroblasts", Am J Pathol., April 2001, Vol. 158(4): pp. 1451-1463.			
		M. Popkov et al., "Rabbit immune repertoires as sources for therapeutic monoclonal antibodies", J. Mol Biol., January 2003, Vol. 325, pp. 325-335.			
		R. Abounader et al., "In vitro targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis", FASEB J, January 2002, Vol. 16(1): pp. 108-110.			
		M. Prat et al., "Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF", J Cell Science, 1998, Vol. 111: pp. 237-247.			

		1	
Examiner Signature	Date Considered	i e	
Zanatare Signature	Date Constucted		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.